

APEX BIOVENTURES ACQUISITION CORP  
Form 8-K  
January 17, 2008

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 11, 2008**

---

**APEX BIOVENTURES ACQUISITION CORPORATION  
(Exact name of registrant as specified in its charter)**

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>6770</b> (Commission File Number)	<b>20-4997725</b> (IRS Employer Identification No.)
--	---	---

**18 Farm Lane  
Hillsborough, California 94010  
(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (650) 344-3029**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act



#### **ITEM 4.01 Changes in Registrant's Certifying Accountant**

On January 11, 2008, Apex Bioventures Acquisition Corporation (the "Company") was notified that the partners of Goldstein Golub Kessler LLP ("GGK"), the Company's independent registered public accounting firm, became partners of McGladrey & Pullen, LLP in a limited asset purchase agreement and that, as a result thereof, GGK has resigned as independent registered public accounting firm for the Company. McGladrey & Pullen, LLP was engaged on January 17, 2008 as the Company's new independent registered public accounting firm.

The audit reports of GGK on the financial statements of Apex Bioventures Acquisition Corporation at June 13, 2007, February 28, 2007, December 31, 2006 and June 30, 2006 and the related statements of operations, stockholders' equity and cash flows for the cumulative period from June 1, 2006 (inception) to June 13, 2007, the period from January 1, 2007 to June 13, 2007, the period from January 1, 2007 to February 28, 2007, the cumulative period from June 1, 2006 (inception) to February 28, 2007, the period from June 1, 2006 to December 31, 2006 and the period from June 1, 2006 (inception) to June 30, 2006 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles except that the audit report on the financial statements for the period ended February 28, 2007 and December 31, 2006 included a going concern explanatory paragraph.

The decision to engage McGladrey & Pullen, LLP was approved by the audit committee of the Company's board of directors.

During the Company's initial audit period from June 1, 2006 (inception) to December 31, 2006, and through the date of this Current Report, the Company did not consult with McGladrey & Pullen, LLP on (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that may be rendered on the Company's financial statements, and McGladrey & Pullen, LLP did not provide either a written report or oral advice to the Company that McGladrey & Pullen, LLP concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; or (ii) any matter that was the subject of any disagreement, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions, or a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

During the period from June 1, 2006 (inception) to December 31, 2006 and through the date of this Current Report, there were: (i) no disagreements between the Company and GGK on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of GGK, would have caused GGK to make reference to the subject matter of the disagreement in their reports on the Company's financial statements for such years, and (ii) no reportable events within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

The Company has provided GGK a copy of the disclosures in this Form 8-K prior to the filing with the Securities and Exchange Commission ("SEC") and has requested that GGK furnish it with a letter addressed to the SEC stating whether or not GGK agrees with the Company's statements in this Item 4.01. A copy of the letter dated January 17, 2008 furnished by GGK in response to that request is filed as Exhibit 99.1 to this Form 8-K.

#### **ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits.

99.1 Letter furnished by GCK in response to the Company's request, addressed to the Securities and Exchange Commission, dated January 17, 2008, indicating their agreement with the statements contained in the Form 8-K filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**APEX BIOVENTURES ACQUISITION  
CORPORATION**

/s/ Darrell J. Elliott

---

Darrell J. Elliott  
Chairman and Chief Executive Officer

Dated January 17, 2008

---

EXHIBIT INDEX

Exhibit Number

Description

99.1

Letter of Goldstein Golub Kessler LLP, dated January 17,  
2008

---